Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds

          Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMedsJuly 28, 2025 7:30 AM EDT | Source: Adaptimmune Therapeutics PLCTecelra will continue to be available to patients without interruption US WorldMeds plans to bring lete-cel to market and will continue development of uza-cel in collaboration with GalapagosPurchase price is $55m in cash to be paid upon consummation of the sale with up to $30m in potential future ...